| __timestamp | ImmunityBio, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 49315000 |
| Thursday, January 1, 2015 | 226206000 | 75043000 |
| Friday, January 1, 2016 | 94391000 | 83749000 |
| Sunday, January 1, 2017 | 53821000 | 122682000 |
| Monday, January 1, 2018 | 35463000 | 207761000 |
| Tuesday, January 1, 2019 | 46456000 | 284812000 |
| Wednesday, January 1, 2020 | 71318000 | 317875000 |
| Friday, January 1, 2021 | 135256000 | 282660000 |
| Saturday, January 1, 2022 | 102708000 | 451421000 |
| Sunday, January 1, 2023 | 129620000 | 481871000 |
Data in motion
In the competitive world of biotechnology, operational efficiency is key. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 reveals intriguing insights into the financial strategies of Sarepta Therapeutics, Inc. and ImmunityBio, Inc. Over the past decade, Sarepta has consistently outpaced ImmunityBio in SG&A spending, peaking at nearly 482% higher in 2023. This trend suggests a robust investment in operational infrastructure and market expansion. Meanwhile, ImmunityBio's expenses have shown a more volatile pattern, with a significant spike in 2015, indicating strategic shifts or one-time investments. Understanding these financial dynamics provides a window into each company's growth strategy and market positioning. As the biotech landscape evolves, monitoring these expenses can offer valuable foresight into future industry leaders.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ImmunityBio, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.